Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction. Issue 2 (February 2019)

• Record Type: Journal Article
• Authors: Sim, Doo Sun; Jeong, Myung Ho; Kim, Hyo Soo; Gwon, Hyeon Cheol; Seung, Ki Bae; Rha, Seung Woon; Chae, Shung Chull; Kim, Chong Jin; Cha, Kwang Soo; Park, Jong Sun; Yoon, Jung Han; Chae, Jei Keon; Joo, Seung Jae; Choi, Dong Ju; Hur, Seung Ho; Seong, In Whan; Cho, Myeong Chan; Kim, Doo Il; Oh, Seok Kyu; Ahn, Tae Hoon; Hwang, Jin Yong
• Is Part Of: Journal of cardiology. Volume 73:Issue 2(2019)
• Page Start: 142
• Page End: 150
• Publication Date: 2019-02
• Subjects: Antiplatelet agents -- Drug-eluting stents -- Myocardial infarction; Cardiology -- Periodicals; 616.12
• DOI: 10.1016/j.jjcc.2018.09.002
• Languages: English
• ISSNs: 0914-5087

Abstract

Highlights: Non-ST-segment elevation myocardial infarction (NSTEMI) patients with higher ischemic and bleeding risks often receive clopidogrel. Potent P2Y12 blockers for NSTEMI reduced ischemic risk but increased bleeding risk. Earlier percutaneous coronary intervention and radial artery access reduced the risk of bleeding in NSTEMI. The optimal dual antiplatelet therapy regimen in Asian patients with NSTEMI needs to be determined. Abstract: Background: Potent P2Y12 blockers are preferred in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI). However, the risk of bleeding remains a major concern. We assessed the association of potent P2Y12 blockers with ischemic and bleeding outcomes in patients with NSTEMI. Methods: From the Korea Acute Myocardial Infarction Registry-National Institute of Health database, 4927 patients with NSTEMI receiving drug-eluting stents (DES) were divided into potent P2Y12 blocker (ticagrelor or prasugrel, n = 901) and clopidogrel ( n = 3180) groups. Propensity-matched 12-month ischemic and bleeding events were compared. Patients who received anticoagulants or who discontinued P2Y12 blockers or switched between potent P2Y12 blockers and clopidogrel were excluded. Results: In the overall population, patients at higher ischemic and bleeding risks more often received clopidogrel. After propensity matching ( n = 901 in each group), 12-month rates of major adverse cardiac and cerebrovascular events were lower (7.3% vs. 10.1%, p = 0.038), but Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding rates were higher (5.9% vs. 2.2%, p < 0.001) with potent P2Y12 blockers. Twelve-month rates of death from any cause, MI, stroke, or TIMI major bleeding were not different. On multivariate analysis, 12-month risk of TIMI major or minor bleeding was higher with B2 or C lesion, potent P2Y12 blocker use, body weight <60 kg, and lower with time to PCI <12 h and radial artery access. Conclusions: In patients with NSTEMI receiving DES, potent P2Y12 blockers were associated with reduced ischemic but increased bleeding risk with similar net clinical benefits.